Anti-human GITR Monoclonal Antibody TRX518 clinical trials
Also written TRX518.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How each study uses Anti-human GITR Monoclonal Antibody TRX518 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- TRX518
- 2
Studies by the year they started
3 studies that test it; most in 2010 (1)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2016 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Leap Therapeutics, Inc. (3)
Studies
Open first, then newest update. How each study uses Anti-human GITR Monoclonal Antibody TRX518 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or NivolumabCompletedPhase 1Leap Therapeutics, Inc.NCT02628574Written as TRX518 monotherapyHow we know
- Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid TumorsCompletedPhase 1Leap Therapeutics, Inc.NCT01239134Written as TRX518How we know
- A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid TumorsTerminatedPhase 1Leap Therapeutics, Inc.NCT03861403Written as TRX518How we know